726 related articles for article (PubMed ID: 29595510)
1. Safety and immunogenicity of the novel tuberculosis vaccine ID93 + GLA-SE in BCG-vaccinated healthy adults in South Africa: a randomised, double-blind, placebo-controlled phase 1 trial.
Penn-Nicholson A; Tameris M; Smit E; Day TA; Musvosvi M; Jayashankar L; Vergara J; Mabwe S; Bilek N; Geldenhuys H; Luabeya AK; Ellis R; Ginsberg AM; Hanekom WA; Reed SG; Coler RN; Scriba TJ; Hatherill M;
Lancet Respir Med; 2018 Apr; 6(4):287-298. PubMed ID: 29595510
[TBL] [Abstract][Full Text] [Related]
2. Safety and immunogenicity of the adjunct therapeutic vaccine ID93 + GLA-SE in adults who have completed treatment for tuberculosis: a randomised, double-blind, placebo-controlled, phase 2a trial.
Day TA; Penn-Nicholson A; Luabeya AKK; Fiore-Gartland A; Du Plessis N; Loxton AG; Vergara J; Rolf TA; Reid TD; Toefy A; Shenje J; Geldenhuys H; Tameris M; Mabwe S; Bilek N; Bekker LG; Diacon A; Walzl G; Ashman J; Frevol A; Sagawa ZK; Lindestam Arlehamn C; Sette A; Reed SG; Coler RN; Scriba TJ; Hatherill M;
Lancet Respir Med; 2021 Apr; 9(4):373-386. PubMed ID: 33306991
[TBL] [Abstract][Full Text] [Related]
3. Live-attenuated Mycobacterium tuberculosis vaccine MTBVAC versus BCG in adults and neonates: a randomised controlled, double-blind dose-escalation trial.
Tameris M; Mearns H; Penn-Nicholson A; Gregg Y; Bilek N; Mabwe S; Geldenhuys H; Shenje J; Luabeya AKK; Murillo I; Doce J; Aguilo N; Marinova D; Puentes E; Rodríguez E; Gonzalo-Asensio J; Fritzell B; Thole J; Martin C; Scriba TJ; Hatherill M;
Lancet Respir Med; 2019 Sep; 7(9):757-770. PubMed ID: 31416768
[TBL] [Abstract][Full Text] [Related]
4. Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV-1: a randomised, placebo-controlled, phase 2 trial.
Ndiaye BP; Thienemann F; Ota M; Landry BS; Camara M; Dièye S; Dieye TN; Esmail H; Goliath R; Huygen K; January V; Ndiaye I; Oni T; Raine M; Romano M; Satti I; Sutton S; Thiam A; Wilkinson KA; Mboup S; Wilkinson RJ; McShane H;
Lancet Respir Med; 2015 Mar; 3(3):190-200. PubMed ID: 25726088
[TBL] [Abstract][Full Text] [Related]
5. Safety and Immunogenicity of the ID93 + GLA-SE Tuberculosis Vaccine in BCG-Vaccinated Healthy Adults: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial.
Choi YH; Kang YA; Park KJ; Choi JC; Cho KG; Ko DY; Ahn JH; Lee B; Ahn E; Woo YJ; Jung K; Kim NY; Reese VA; Larsen SE; Baldwin SL; Reed SG; Coler RN; Lee H; Cho SN
Infect Dis Ther; 2023 Jun; 12(6):1605-1624. PubMed ID: 37166567
[TBL] [Abstract][Full Text] [Related]
6. The safety and immunogenicity of an adenovirus type 35-vectored TB vaccine in HIV-infected, BCG-vaccinated adults with CD4(+) T cell counts >350 cells/mm(3).
Churchyard GJ; Snowden MA; Hokey D; Dheenadhayalan V; McClain JB; Douoguih M; Pau MG; Sadoff J; Landry B
Vaccine; 2015 Apr; 33(15):1890-6. PubMed ID: 25698492
[TBL] [Abstract][Full Text] [Related]
7. The tuberculosis vaccine H4:IC31 is safe and induces a persistent polyfunctional CD4 T cell response in South African adults: A randomized controlled trial.
Geldenhuys H; Mearns H; Miles DJ; Tameris M; Hokey D; Shi Z; Bennett S; Andersen P; Kromann I; Hoff ST; Hanekom WA; Mahomed H; Hatherill M; Scriba TJ; ; van Rooyen M; Bruce McClain J; Ryall R; de Bruyn G;
Vaccine; 2015 Jul; 33(30):3592-9. PubMed ID: 26048780
[TBL] [Abstract][Full Text] [Related]
8. Safety and immunogenicity of the rVSV∆G-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study.
Heppner DG; Kemp TL; Martin BK; Ramsey WJ; Nichols R; Dasen EJ; Link CJ; Das R; Xu ZJ; Sheldon EA; Nowak TA; Monath TP;
Lancet Infect Dis; 2017 Aug; 17(8):854-866. PubMed ID: 28606591
[TBL] [Abstract][Full Text] [Related]
9. Adenovirus type 35-vectored tuberculosis vaccine has an acceptable safety and tolerability profile in healthy, BCG-vaccinated, QuantiFERON(®)-TB Gold (+) Kenyan adults without evidence of tuberculosis.
Walsh DS; Owira V; Polhemus M; Otieno L; Andagalu B; Ogutu B; Waitumbi J; Hawkridge A; Shepherd B; Pau MG; Sadoff J; Douoguih M; McClain JB;
Vaccine; 2016 May; 34(21):2430-2436. PubMed ID: 27026148
[TBL] [Abstract][Full Text] [Related]
10. Safety and immunogenicity of a parenteral trivalent P2-VP8 subunit rotavirus vaccine: a multisite, randomised, double-blind, placebo-controlled trial.
Groome MJ; Fairlie L; Morrison J; Fix A; Koen A; Masenya M; Jose L; Madhi SA; Page N; McNeal M; Dally L; Cho I; Power M; Flores J; Cryz S
Lancet Infect Dis; 2020 Jul; 20(7):851-863. PubMed ID: 32251641
[TBL] [Abstract][Full Text] [Related]
11. PRIMVAC vaccine adjuvanted with Alhydrogel or GLA-SE to prevent placental malaria: a first-in-human, randomised, double-blind, placebo-controlled study.
Sirima SB; Richert L; Chêne A; Konate AT; Campion C; Dechavanne S; Semblat JP; Benhamouda N; Bahuaud M; Loulergue P; Ouédraogo A; Nébié I; Kabore M; Kargougou D; Barry A; Ouattara SM; Boilet V; Allais F; Roguet G; Havelange N; Lopez-Perez E; Kuppers A; Konaté E; Roussillon C; Kanté M; Belarbi L; Diarra A; Henry N; Soulama I; Ouédraogo A; Esperou H; Leroy O; Batteux F; Tartour E; Viebig NK; Thiebaut R; Launay O; Gamain B
Lancet Infect Dis; 2020 May; 20(5):585-597. PubMed ID: 32032566
[TBL] [Abstract][Full Text] [Related]
12. Safety of human immunisation with a live-attenuated Mycobacterium tuberculosis vaccine: a randomised, double-blind, controlled phase I trial.
Spertini F; Audran R; Chakour R; Karoui O; Steiner-Monard V; Thierry AC; Mayor CE; Rettby N; Jaton K; Vallotton L; Lazor-Blanchet C; Doce J; Puentes E; Marinova D; Aguilo N; Martin C
Lancet Respir Med; 2015 Dec; 3(12):953-62. PubMed ID: 26598141
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial.
Tameris MD; Hatherill M; Landry BS; Scriba TJ; Snowden MA; Lockhart S; Shea JE; McClain JB; Hussey GD; Hanekom WA; Mahomed H; McShane H;
Lancet; 2013 Mar; 381(9871):1021-8. PubMed ID: 23391465
[TBL] [Abstract][Full Text] [Related]
14. Safety and immunogenicity of an investigational maternal trivalent group B streptococcus vaccine in healthy women and their infants: a randomised phase 1b/2 trial.
Madhi SA; Cutland CL; Jose L; Koen A; Govender N; Wittke F; Olugbosi M; Meulen AS; Baker S; Dull PM; Narasimhan V; Slobod K
Lancet Infect Dis; 2016 Aug; 16(8):923-34. PubMed ID: 27139805
[TBL] [Abstract][Full Text] [Related]
15. A double-blind, randomised, placebo-controlled, dose-finding trial of the novel tuberculosis vaccine AERAS-402, an adenovirus-vectored fusion protein, in healthy, BCG-vaccinated infants.
Tameris M; Hokey DA; Nduba V; Sacarlal J; Laher F; Kiringa G; Gondo K; Lazarus EM; Gray GE; Nachman S; Mahomed H; Downing K; Abel B; Scriba TJ; McClain JB; Pau MG; Hendriks J; Dheenadhayalan V; Ishmukhamedov S; Luabeya AK; Geldenhuys H; Shepherd B; Blatner G; Cardenas V; Walker R; Hanekom WA; Sadoff J; Douoguih M; Barker L; Hatherill M
Vaccine; 2015 Jun; 33(25):2944-54. PubMed ID: 25936724
[TBL] [Abstract][Full Text] [Related]
16. Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial.
Pollard AJ; Launay O; Lelievre JD; Lacabaratz C; Grande S; Goldstein N; Robinson C; Gaddah A; Bockstal V; Wiedemann A; Leyssen M; Luhn K; Richert L; Bétard C; Gibani MM; Clutterbuck EA; Snape MD; Levy Y; Douoguih M; Thiebaut R;
Lancet Infect Dis; 2021 Apr; 21(4):493-506. PubMed ID: 33217361
[TBL] [Abstract][Full Text] [Related]
17. Dose Optimization of H56:IC31 Vaccine for Tuberculosis-Endemic Populations. A Double-Blind, Placebo-controlled, Dose-Selection Trial.
Suliman S; Luabeya AKK; Geldenhuys H; Tameris M; Hoff ST; Shi Z; Tait D; Kromann I; Ruhwald M; Rutkowski KT; Shepherd B; Hokey D; Ginsberg AM; Hanekom WA; Andersen P; Scriba TJ; Hatherill M;
Am J Respir Crit Care Med; 2019 Jan; 199(2):220-231. PubMed ID: 30092143
[TBL] [Abstract][Full Text] [Related]
18. Safety and immunogenicity of a parenteral P2-VP8-P[8] subunit rotavirus vaccine in toddlers and infants in South Africa: a randomised, double-blind, placebo-controlled trial.
Groome MJ; Koen A; Fix A; Page N; Jose L; Madhi SA; McNeal M; Dally L; Cho I; Power M; Flores J; Cryz S
Lancet Infect Dis; 2017 Aug; 17(8):843-853. PubMed ID: 28483414
[TBL] [Abstract][Full Text] [Related]
19. Safety and immunogenicity of a synthetic carbohydrate conjugate vaccine against Shigella flexneri 2a in healthy adult volunteers: a phase 1, dose-escalating, single-blind, randomised, placebo-controlled study.
Cohen D; Atsmon J; Artaud C; Meron-Sudai S; Gougeon ML; Bialik A; Goren S; Asato V; Ariel-Cohen O; Reizis A; Dorman A; Hoitink CWG; Westdijk J; Ashkenazi S; Sansonetti P; Mulard LA; Phalipon A
Lancet Infect Dis; 2021 Apr; 21(4):546-558. PubMed ID: 33186516
[TBL] [Abstract][Full Text] [Related]
20. Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trial.
Chappell KJ; Mordant FL; Li Z; Wijesundara DK; Ellenberg P; Lackenby JA; Cheung STM; Modhiran N; Avumegah MS; Henderson CL; Hoger K; Griffin P; Bennet J; Hensen L; Zhang W; Nguyen THO; Marrero-Hernandez S; Selva KJ; Chung AW; Tran MH; Tapley P; Barnes J; Reading PC; Nicholson S; Corby S; Holgate T; Wines BD; Hogarth PM; Kedzierska K; Purcell DFJ; Ranasinghe C; Subbarao K; Watterson D; Young PR; Munro TP
Lancet Infect Dis; 2021 Oct; 21(10):1383-1394. PubMed ID: 33887208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
